MFT Inhibitors

MFT inhibitors primarily revolve around compounds that target the folate metabolism pathway. Since MFT is a key player in the transport of folates into mitochondria, affecting the availability or metabolism of these folates can indirectly affect MFT's function. Methotrexate, Pemetrexed, and Pyrimethamine, for instance, hinder enzymes vital to folate metabolism, like dihydrofolate reductase. With the disruption of these enzymes, the intracellular folate pool can diminish, leading to reduced substrate availability for MFT transport.

On the other hand, compounds like Raltitrexed and 5-Fluorouracil specifically target thymidylate synthase, an enzyme critical in the folate pathway. Any disturbance to this enzyme can indirectly affect MFT's transport role. Other compounds, such as 6-Mercaptopurine and Thymidine, introduce an indirect effect. By altering related pathways, such as purine metabolism, they can influence the folate pathway and, by extension, MFT's function. Lastly, agents like Folinic acid (Leucovorin) can introduce a potential feedback mechanism. Excessive amounts of active folates might saturate the system, indirectly inhibiting MFT's role.